Considerations for the Treatment Strategy of Relapse After Tofacitinib Therapy in Alopecia Areata

Alopecia areata (AA) is an autoimmune disorder that can be treated with JAK inhibitors like tofacitinib, but relapse is common, affecting 58% of patients. A case study of a 26-year-old female with alopecia universalis showed initial improvement with tofacitinib, but hair loss resumed, leading to a switch to ritlecitinib. The study suggests that personalized treatment strategies and combination therapies are necessary to maintain remission. JAK inhibitors work by suppressing immune attacks and promoting hair follicle stem cell proliferation. Monitoring biomarkers related to immune response and hair follicle signaling pathways can help evaluate treatment efficacy. Strategies to manage relapse include combined drug therapy, increasing the tofacitinib dose, or switching to other JAK inhibitors, while considering the risks of serious side effects.